FindTrial
Sign In

Prediction of Salivary Gland Function Impairment in Patients with Differentiated Thyroid Cancer Induced by 131I Treatment Using Salivary Gland Scintillation Imaging

Prediction of Salivary Gland Function Impairment in Patients with Differentiated Thyroid Cancer Induced by 131I Treatment Using Salivary Gland Scintillation Imaging

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400091997
Enrollment
Unknown
Registered
2024-11-07
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid cancer

Interventions

Trail group:NA

Sponsors

Xuzhou Medical University Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: From 2020 to 2022, he was hospitalized twice for 131I radionuclides in the Department of Nuclear Medicine of our hospital after DTC, and both times he underwent salivary gland scintigraphy under the same conditions

Exclusion criteria

Exclusion criteria: (1) Patients who have previously received chemotherapy and/or radiation therapy for any other malignant tumors; (2) There are related diseases, such as Sjogren's syndrome, salivary gland lumps, human immunodeficiency virus infection or autoimmune diseases, and previous salivary gland inflammation.

Design outcomes

Primary

MeasureTime frame
uptake index(UI);—

Secondary

MeasureTime frame
excretion fraction(EF);Variations in uptake index(?UI%);—

Countries

China

Contacts

Public ContactZhu Hui

Xuzhou Medical University Affiliated Hospital

958520907@qq.com+86 139 1345 5100

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026